Compare Gilead Sciences, Inc. (GILD) vs Union Pacific Corporation (UNP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Union Pacific Corporation — how do they compare? Gilead Sciences, Inc. trades at $135.78 (market cap $168.35B), while Union Pacific Corporation trades at $293.53 (market cap $173.99B). The key difference: Gilead Sciences, Inc. and Union Pacific Corporation are close in size by market cap, and Gilead Sciences, Inc. pays the higher dividend (2.42%). Which is the better fit depends on your goals.
| GILD | UNP | |
|---|---|---|
Market Cap | $168.35B | $173.99B |
Sector | Health | Industrials |
52-Week High | $155.80 | $307.32 |
52-Week Low | $110.56 | $214.91 |
Enterprise Value | $191.42B | $203.04B |
Dividend Yield | 2.42% | 1.94% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $136.73, up 2.76% on the day, with a bullish technical signal and strong analyst consensus. Recent Q2 2026 earnings beat revenue estimates despite a net loss driven by acquisition costs, while HIV drug sales and raised guidance provide fundamental support. The stock is near its pivot point of $136, with resistance at $137 and support at $134.
Outlook remains positive given robust HIV franchise growth and pipeline advancements, but risks include patent cliffs, high debt, and profitability volatility. With 67% of analysts rating it a Buy and a consensus price target of $151.22, the stock offers potential upside, though investors must weigh execution risks against growth catalysts.
Union Pacific (UNP) trades at $293.85, up 0.55% with neutral technical signals. The company demonstrates strong fundamentals with Q2 2026 EPS beating estimates at $3.41 versus $3.26 expected, marking the second consecutive quarterly beat. Revenue growth of 12% year-over-year and improved operating efficiency support management's raised full-year EPS guidance. The stock maintains robust profitability metrics including 28.85% net margin and 39.7% ROE, though valuation multiples remain elevated with P/E at 23.71.
Outlook remains positive with analyst consensus price target of $334.33 representing 14% upside potential. Key catalysts include service-led growth driving margin expansion and the pending Norfolk Southern merger offering strategic benefits. Risks include high fuel costs, regulatory scrutiny of the merger, and macroeconomic pressures on freight volumes. Institutional ownership trends show continued accumulation by major funds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Union Pacific Corporation
Omaha, Nebraska-based Union Pacific is the largest public railroad in North America. Operating on more than 30,000 miles of track in the western two thirds of the U.S., UP generated roughly $22 billion of revenue in 2021 by hauling coal, industrial products, intermodal containers, agriculture goods, chemicals, and automotive goods. UP owns about one fourth of Mexican railroad Ferromex and derives about 10% of its revenue hauling freight to and from Mexico.
Read more on UNP →
